Compass Therapeutics (CMPX) announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. Most recently, he served as Executive Vice President, Chief Operating Officer & Chief Financial Officer at Trevena (TRVN).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass downgrade ‘curious,’ presents upside, says H.C. Wainwright
- Compass Therapeutics downgraded to Market Perform from Outperform at Leerink
- Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress
- Compass Therapeutics price target raised to $7 from $5 at Ladenburg
- Compass Therapeutics reports Q3 EPS (8c), consensus (11c)